As part of the digital health roadmap, G_nius is “a service and content portal for all entrepreneurs who create digital health services”, she summarized. It is aimed more particularly at start-ups, but all players in the sector can find useful information there.
The counter recently acquired a practical sheet entitled “working with the drug industry“.
It was designed by Leem (The drug companies), and the ANS ensured that it was “pragmatic” and “concrete”, indicated Anne Bertaud.
The ANS proposed to Leem to create a document “explaining what it means to work with the drug industry” and in particular listing “the questions that entrepreneurs must ask themselves before starting out”.
“Are the therapeutic and / or technological areas of my project aligned with those of the laboratory? Am I ready to integrate an industrialist into the capital of my company? How will the results of the project be valued through publications and how will be shared intellectual property elements? Am I ready to grant partnership exclusivity to a laboratory for the duration of the support, in one or more countries? “
The page indicates the different types of support programs offered by drug companies, lists a few examples including those of AstraZeneca, Roche, Pfizer, Sanofi, Novartis and Janssen (Johnson & Johnson group, J&J), and gives advice to prepare an application.
It also provides “keys for reflection” on their economic model to project leaders.
It is intended to be “updated once a quarter, during a meeting with the players, to add any new programs or projects”.
The counter site is constantly evolving and suggestions are welcome, said the manager.
This page is the first in a “working with” series. The next ones will concern mutuals and insurance companies, health establishments, even the medical device industry (MD) “for which there will be something to do”.
“A large part of our action, before the launch of G_nius, was to meet as many ecosystem players as possible. We have permanent exchanges, and during our discussions with Leem, a subject emerged: how to work with the pharmaceutical industry? “, recounted Anne Bertaud.
Asked about a possible fear of companies to see competition in access to innovative start-ups accentuated by this device, the project manager stressed that “the file is not carried by a single private actor, but by a federation which represents the entire industry “.
“The writing criteria are objective and unambiguous. It is not a question of listing the best programs or indicating a specific number,” she added.
“Large groups have learned things”
–
In addition, the ANS has created fact sheets “on the actors of the ecosystem, the regulatory framework, and economic models.” They are mainly aimed at start-ups, but “large groups have made it known that they had learned things”.
“Entrepreneurs do not have time to look for information, so we offer them actionable, concrete information. The aim is not to duplicate the sites of institutions or to educate entrepreneurs in general,” added Anne Bertaud. .
The ANS uses the term entrepreneurs, but the G_nius counter is aimed at “all those who design digital services in health, health professionals, large groups, associations” as well as start-ups, she specified. .
Feedback from entrepreneurs is positive, the site having “a very good visit rate” with an increase in loyalty. It has 62,000 page views and 22,000 unique visitors. The ANS podcast, 100 days to succeed, which presents “feedback from entrepreneurs”, reached 3,200 downloads.
As for manufacturers, “they are positive, but rather as consumers of G_nius services. They appreciate concrete information. We also receive proposals for contributions from federations or unions such as Snitem.”
The ANS has not planned for extensive monitoring of the contacts that have emerged thanks to the one-stop shop because “it is not intended to support each entrepreneur individually”, but its partners, clusters and competitiveness clusters, “are well placed “to provide this support.
–
